secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silo Pharma, Inc. (SILO)
CIK:        0001514183
Form:       8-K
Filed at:   2025-07-10T23:59:59+00:00
Accession:  0001213900-25-062805
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silo Pharma terminates UMB license, enters evaluation license and option for CNS-homing peptides
--------------------------------------------------------------------------------

- Terminates 2021 Master License Agreement with University of Maryland, Baltimore effective June 30, 2025.
- Gains exclusive evaluation license for CNS-homing peptides for non-clinical research through March 31, 2026.
- Holds option to negotiate a commercial license for neuroinflammatory disease; exercise requires $1,000 fee and plan.
- Derived IP created during evaluation automatically assigned to UMB; if option exercised, it enters new license.
- U.S. Government retains rights under Federal IP Policy; agreement subject to existing third-party commitments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1514183/000121390025062805/0001213900-25-062805-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1514183/000121390025062805/ea0248611-8k_silo.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-062805

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer